Manufacturing

Sun Pharma launches ready-to-infuse INFUGEM in the US

Sun Pharmaceutical Industries Ltd. announced that INFUGEM (gemcitabine in sodium chloride injection), for intravenous use, is now commercially available in the U.S.

Merck invests in expansion of manufacturing capacity for biotech medicines

Merck, a leading science and technology company, has announced an investment of €150m in its manufacturing site at Aubonne, Switzerland, to expand manufacturing capacity for its biotech medicines.

bluebird bio opens gene and cell therapy manufacturing facility in North Carolina

bluebird bio announced the official opening of its first wholly owned manufacturing facility in Durham, N.C., that will produce lentiviral vector for the company’s investigational gene and cell therapies, including: bb2121 and bb21217 for the treatment of multiple myeloma and potentially LentiGlobin for the treatment of transfusion-dependent β-thalassemia (TDT) and sickle cell disease.

Blackstone to buy Japanese specialty pharmaceutical firm Ayumi

Blackstone-managed private equity funds have agreed to acquire Japanese specialty pharmaceutical firm Ayumi Pharmaceutical from an independent private equity firm Unison Capital.

Fujifilm to buy Biogen’s Danish biologics manufacturing site for $890m

Fujifilm has agreed to acquire to acquire Biogen (Denmark) Manufacturing ApS, a large-scale biologics manufacturing site located in Hillerød near Copenhagen, Denmark (Biogen Hillerød), for about $890m in cash.

Sagent Pharmaceuticals announces acquisition of Raleigh manufacturing site

Nichi-Iko Pharmaceutical and Sagent Pharmaceuticals, a Nichi-Iko Group Company ("Sagent"), a leader of specialty pharmaceutical products with an emphasis on the injectable market, announced that Sagent has acquired an FDA-approved manufacturing site in Raleigh, North Carolina, from Xellia Pharmaceuticals ("Xellia").

Danaher agrees to buy GE’s biopharma business for $21.4bn

Science and technology firm Danaher has agreed to acquire the biopharma business of GE Life Sciences (GE Biopharma) for a cash purchase price of about $21.4bn.

Neuraxpharm acquires CNS specialty pharma company Farmax

Neuraxpharm Group, a European specialty pharmaceutical company focused on the treatment of central nervous system disorders (CNS), has announced the acquisition of Farmax, a CNS specialty pharmaceutical company, from SVUS Pharma.

Hitachi Chemical to acquire apceth Biopharma

apceth Biopharma, a contract manufacturing organization in the field of cell and gene therapy, announced that Hitachi Chemical Co., Ltd. will enter into an agreement to acquire all shares of apceth Biopharma.